Evaluating Dashboard-Integrated Pharmacist-Led Education on Improving Sacubitril/Valsartan Adherence in Heart Failure (PharmD ASSIST HFrEF)

National Taiwan University

Status: Not yet enrolling

Conditions: Medication Adherence; Sacubitril/Valsartan; Heart Failure With Reduced Ejection Fraction (HFrEF)

Treatments: Device: interactive visualization dashboard (the Enhancing Sacubitril/valsartan Adherence from Initiation to Continuation [ESAIC] dashboard)

Study type: Interventional

Funder types: Other

Identifiers

NCT06900803

202501197RINC

Details and patient eligibility

About

The goal of this pragmatic clinical trial is to evaluate whether pharmacist-led education, integrated with interactive visualization dashboards, can enhance medication adherence in patients with heart failure who are prescribed sacubitril/valsartan. The main question it aims to answer is: Can pharmacist-led interactive visualization dashboards improve adherence to sacubitril/valsartan compared to usual care without the dashboard intervention?

Researchers will compare patients receiving pharmacist-led education with interactive dashboards to those receiving standard education, assessing differences in medication adherence and clinical outcomes, among others.

Participants will:

• Complete baseline and follow-up questionnaires on medication adherence and satisfaction with pharmacist-provided services, and others.
• Engage in education sessions led by pharmacists, with or without dashboard integration.

The study outcomes will include medication adherence, and secondary outcomes such as patient satisfaction with pharmacist-provided services, optimized guideline-directed medical therapy score, time to high medication adherence, the calculated proportion of days covered, New York Heart Association functional classification, and the net promoter score used for evaluating recommendation and satisfaction with the dashboard intervention.

Enrollment: 200 estimated patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• adults aged 20 or older
• a diagnosis of HFrEF, which is defined by a left ventricular ejection fraction of 40% or less
• currently receiving sacubitril/valsartan at the time of recruitment
• receiving care at the cardiology department or cardiology ward at National Taiwan University Hospital
• referral from the clinicians at National Taiwan University Hospital

Exclusion criteria

• unable or unwilling to provide informed consent, adhere to study protocols, or complete required questionnaires in person during three scheduled visits (i.e., 3, 6, 12 months after the baseline measurement)
• having received care at the pharmacist-led HF clinic at National Taiwan University Hospital

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

200 participants in 4 patient groups

Low Adherence Cluster - Intervention Group

Experimental group

Description:

Dashboard interventions integrated into pharmacist-led education in the low adherence cluster

Treatment:

Device: interactive visualization dashboard (the Enhancing Sacubitril/valsartan Adherence from Initiation to Continuation [ESAIC] dashboard)

Low Adherence Cluster - Control Group

No Intervention group

Description:

Pragmatic pharmacist-led education, without dashboard interventions, in the low adherence cluster

High Adherence Cluster - Intervention Group

Experimental group

Description:

Dashboard interventions integrated into pharmacist-led education in the high adherence cluster

Treatment:

Device: interactive visualization dashboard (the Enhancing Sacubitril/valsartan Adherence from Initiation to Continuation [ESAIC] dashboard)

High Adherence Cluster - Control Group

No Intervention group

Description:

Pragmatic pharmacist-led education, without dashboard interventions, in the high adherence cluster